Arbutus Biopharma Corporation (ABUS)
Stock Price:
$4.34 USD
0.57 (15.12%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $4.40 +0.06 (1.38%) Nov 27, 4:54 PM
Key Info
| Market Cap |
368.51M |
| Revenue (ttm) |
6.15M |
| Net Income (ttm) |
-83.24M |
| Shares Out |
84.91M |
| EPS (ttm) |
-1.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$4.34 |
| Previous Close |
$3.77 |
| Change ($) |
0.57 |
| Change (%) |
15.12% |
| Day's Open |
4.00 |
| Day's Range |
3.95 - 4.56 |
| Day's Volume |
5,344,897 |
| 52-Week Range |
0.88 - 9.02 |
More Stats
| Market Cap |
368.51M |
| Enterprise Value |
253.32M |
| Earnings Date (est) |
Mar 11, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
84.91M |
| Float |
61.55M |
| EPS (basic) |
-1.23 |
| EPS (diluted) |
-1.21 |
| FCF / Share |
-0.63 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.66M |
| Short Ratio |
1.76 |
| Short % of Float |
4.31% |
| Beta |
3.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
59.96 |
| PB Ratio |
2.44 |
| Revenue |
6.15M |
| Operating Income |
-54.24M |
| Net Income |
-83.24M |
| Free Cash Flow |
-49.92M |
| Net Cash |
115.19M |
| Net Cash / Share |
1.36 |
| Gross Margin |
-839.41% |
| Operating Margin |
-882.59% |
| Profit Margin |
-1,354.30% |
| FCF Margin |
-812.22% |
| ROA |
-25.05% |
| ROE |
-78.86% |
| ROIC |
-120.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.40*
(47.47% upside)
Low
4.00
Current: $4.34
High
8.00
Target: 6.40
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 6.01 | 5.95 | 10.70 | 1.49 | 23.28 | 14.95 | 15.47 | 14.11 | 16.81 |
| Revenue Growth | 1.11% | -44.44% | 617.64% | -93.59% | 55.66% | -3.31% | 9.64% | -16.1% | - |
| Gross Profit | 6.01 | 5.95 | 10.70 | 1.49 | 23.28 | 14.95 | 15.47 | 14.11 | 16.81 |
| Operating Income | -144 | -89.78 | -111 | -492 | -104 | -33.43 | -12.15 | -12.95 | -10.69 |
| Net Income | -154 | -57.06 | -84.41 | -384 | -62.72 | -38.84 | -14.06 | 29.61 | -10.08 |
| Shares Outstanding | 57.09 | 55.30 | 54.72 | 53.07 | 45.46 | 21.60 | 15.30 | 13.73 | 11.32 |
| Earnings Per Share | -2.89 | -1.21 | -1.56 | -7.24 | -1.38 | -1.80 | -0.92 | 2.07 | -0.89 |
| Operating Cash Flow | -71.01 | -67.87 | -48.64 | -57.89 | -56.38 | -12.42 | -6.74 | 32.91 | -7.83 |
| Capital Expenditures | -0.58 | -1.11 | -7.26 | -3.97 | -2.29 | -0.98 | -0.73 | -0.01 | -0.06 |
| Free Cash Flow | -71.58 | -68.98 | -55.90 | -61.86 | -58.67 | -13.40 | -7.46 | 32.90 | -7.89 |
| Cash & Equivalents | 90.83 | 125 | 126 | 131 | 181 | 112 | 68.72 | 47.02 | - |
| Total Debt | 3.02 | - | 12.00 | 12.00 | - | - | - | - | - |
| Net Cash / Debt | 87.82 | 125 | 114 | 119 | 181 | 112 | 68.72 | 47.02 | - |
| Assets | 106 | 228 | 237 | 276 | 712 | 118 | 71.72 | 52.60 | - |
| Liabilities | 32.79 | 27.67 | 54.69 | 72.91 | 165 | 30.14 | 12.52 | 11.68 | - |
| Book Value | 72.74 | 200 | 182 | 203 | 548 | 88.04 | 59.19 | 40.92 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Arbutus Biopharma Corporation |
| Country |
United States |
| Employees |
78 |
| CEO |
William H. Collier |
Stock Information
| Ticker Symbol |
ABUS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ABUS |
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.